Join us as we celebrate the opening of our new and expanded facilities!
The latest in SRFs work & organization
Share the message of Rejuvenation Biotechnology!
Visit our brand new Marketplace to shop our collection of high quality branded items.
SENS Research Foundation works to develop, promote, and ensure widespread access to therapies that cure and prevent the diseases and disabilities of aging by comprehensively repairing the damage that builds up in our bodies over time. We are redefining the way the world researches and treats age-related ill health, while inspiring the next generation of biomedical scientists.
We are happy to announce that Dr. Ravi Jain has joined our team as Vice President of Research. He has previously served as a consultant for SRF and we are very excited to welcome him to his new role. Please visit our TEAM page to learn more about him and our amazing Team.
We are thrilled to open applications for the 2023 Postbaccalaureate and Summer Scholars programs!
The SRF Postbaccalaureate Fellowship Program offers recent graduates a gap year option to strengthen research and communication skills in preparation for opportunities such as graduate & medical programs, and biotech positions.
The SRF Summer Scholars Program offers undergraduate students the opportunity to conduct biomedical research to combat diseases of aging, such as cancer, Alzheimer’s, and Parkinson’s Disease under the guidance of a scientific mentor.
Join us for an impactful learning experience bound to grow you as a scientist and prepare you for your next step in contributing to a future free of age-related disease!
Docuthon is the world’s first documentary-creating competition on AI-powered drug discovery, providing an opportunity for every talented filmmaker to get involved in a cutting-edge industry, share a terrific science story, and inspire the next generation of scientists in longevity.
When blood from a biologically aged animal is transfused into a young one, the young animal suffers “pro-aging” effects. By contrast, reducing the burden of “pro-aging” signaling factors in old blood is not enough to remove existing damage from a similar-aged mouse’s biologically aged tissues.
UNITY Biotechnology was the first senolytic startup out of the gate, and the failure of its Phase II trial in osteoarthritis was a crushing disappointment. A careful look back at the underlying science and three new scientific papers give us a good idea why and suggest ways to move forward.
Sign up to stay informed about the latest news and opportunities with SRF!
Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.
© 2023 SENS Research Foundation – ALL RIGHTS RESERVED
